Regeneron and Bayer Start Phase III Trial of Macular Edema Drug in China
Regeneron Pharmaceuticals and Bayer HealthCare have started a new Phase III trial to test Eylea® (aflibercept) Injection as a treatment for Diabetic Macular Edema (DME). The trial will be conducted in China, Russia and other Asian countries. In its global Phase II DME program, Eylea showed promising results. More details.... Stock Symbols: (NSDQ: REGN) (Xetra: BAY) Share this with colleagues: // //  
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here